November 5th, 2024 – INCATE (the INCubator for Antibacterial Therapies in Europe) is pleased to announce that Shionogi & Co., Ltd., a leader in the discovery and development of treatments for infectious diseases, has extended its collaboration with INCATE, initially launched in 2021.

“This is fantastic news for INCATE,” said Christoph Dehio, Director of NCCR Antiresist and INCATE Board Member. “Shionogi has a longstanding history of combating infectious diseases and remains deeply committed to advancing research and developing new antimicrobial therapies. Their expertise and vast experience in the field have been invaluable in helping INCATE identify the most promising early-stage innovations to tackle this critical issue.”

Hideki Maki, Principal Scientist, Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., stated: “SHIONOGI has a long-standing commitment to addressing critical unmet clinical needs. As a key player in the fight against antimicrobial resistance, our partnership with INCATE aligns perfectly with our mission to protect people from infectious disease threats and to promote healthy, prosperous lives.”

A recent GBD 2021 study in The Lancet estimates that AMR was linked to 4.71 million deaths in 2021, with over one million directly attributable to it. While AMR-related deaths in children under five dropped by 50% from 1990 to 2021, deaths among those aged 70 and older increased by over 80%. This highlights the growing AMR burden among the elderly in a rapidly aging global population.

The study also estimates that by 2050, the AMR burden could rise to 8.22 million associated deaths, with 1.91 million people potentially dying directly from AMR. This represents an annual increase of nearly 75% and 70%, respectively, compared to 2022 figures.

As these figures indicate, urgent action is essential to develop new antimicrobial treatments. Through this extended alliance with Shionogi, INCATE aims to keep on strengthening the support to early-stage innovators globally in creating novel product candidates and technological platforms that can address this escalating crisis.

The INCATE support model has already demonstrated its value for early-stage ventures and will continue to grow, expanding to new regions while strengthening collaborations with both new and existing partners. INCATE remains committed to empowering innovators in the fight against drug-resistant infections.

About Shionogi & Co., Ltd.

Shionogi is committed to “Protect people worldwide from the threat of infectious diseases” as our key focus. We are not only conducting research and development of novel therapeutics, but we are also working towards total care, through building awareness, epidemiologic monitoring, prevention, diagnosis, and addressing exacerbations, as well as treating the infection itself.

For more information, please visit https://www.shionogi.com/global/en/.

About INCATE 

INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, Roche, Shionogi and MSD as well as other organizations, funders and investors, INCATE wants to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.

For more information please contact:

helena.costa.pereira@incate.net or +49 176 46172549
www.incate.net
X: @INCATEurope
YouTube: @INCATEurope
Linkedin: @INCATE